Advertisement

Topics

Obinutuzumab - Biotech, Pharma and Life Science Channel

18:28 EST 19th January 2017 | BioPortfolio

A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.

Source: http://www.cancer.gov/drugdictionary?cdrid=570643

PubMed Articles [6 Associated PubMed Articles listed on BioPortfolio]

Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.

The Phase Ib GERSHWIN study (NCT01680991) assessed the pharmacokinetic (PK) profile of obinutuzumab following multiple intravenous (i.v.) doses to Chinese patients with B-cell lymphomas, and compared ...

Safety and efficacy of Obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.

The GAUDI study assessed safety and preliminary efficacy of induction therapy with obinutuzumab plus chemotherapy, followed by maintenance with obinutuzumab alone, in previously untreated patients wit...

Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.

Obinutuzumab combined with chlorambucil (GClb) has shown to be superior to rituximab combined with chlorambucil (RClb) and chlorambucil (Clb) in newly diagnosed patients with chronic lymphocytic leuka...

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab.

Membranoproliferative glomerulonephritis (MPGN) is a common extramedullary renal presentation in chronic lymphocytic leukemia (CLL) and can present with either a frank renal failure or proteinuria. On...

Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.

Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody (MoAb) with a higher affinity for CD20 epitope. It was approved by the United States Food and Drug Administration (FDA) in...

Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.

News Articles [14 Associated News Articles listed on BioPortfolio]

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxa...

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who h...

[News] 58th American Society of Hematology Annual Meeting

Robert Marcus (Kings College Hospital, London, UK) presented results from the phase 3 randomised GALLIUM Study. Patients with previously untreated follicular lymphoma were randomly allocated to receiv...

Newer Anti-CD20 Drug Prevails in Follicular Lymphoma (CME/CE)

(MedPage Today) -- Better PFS with obinutuzumab but with more adverse events

Obinutuzumab Plus Chemotherapy Lengthens PFS in Follicular Lymphoma

Obinutuzumab-based therapy is superior to rituximab-based therapy in patients with previously untreated advanced follicular lymphoma.

Obinutuzumab Bests Rituximab in Advanced FL

Obinutuzumab for induction and maintenance was better than the current standard of care for follicular lymphoma, but caution is warranted with chemotherapy used as part of induction. ...

Roche’s Gazyva/Gazyvaro Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to MabThera/Rituxan

Roche today announced data from the positive, pivotal Phase III GALLIUM study that compared Gazyva®/Gazyvaro® (obinutuzumab) plus chemotherapy followed by Gazyva/Gazyvaro alone head-to-head against ...

Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial

Dr Davies speaks with ecancertv at ASH 2016 about phase III trials of obinutuzumab, an anti-CD20 monoclonal antibody for the treatment of follicular lymphoma. He describes the influence of pre-trea...

TG Therapeutics slides on ublituximab study changes

TG Therapeutics Inc. (NASDAQ:TGTX) slid $1.41 (17%) to $6.84 on Thursday after amending the ongoing Phase III GENUINE study of ublituximab (TG-1101) to treat chronic lymphocytic leukemia (CLL). The co...

Events [0 Results]

None

Companies [0 Results]

None

Clinical Trials [43 Associated Clinical Trials listed on BioPortfolio]

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

This phase I study studies the side effects and best dose of venetoclax and lenalidomide when given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that ha...

Safety and Efficacy of the Combination of GS-4059 and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

The objective of this study is to determine the preliminary efficacy and safety of the combination of GS-4059 and entospletinib with and without obinutuzumab in adults with relapsed or ref...

Safety and Efficacy of the Combination of GS-4059 and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

The objective of this study is to determine the preliminary efficacy and safety of the combination of GS-4059 and idelalisib with and without obinutuzumab in adults with relapsed or refrac...

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Prospective national multicenter open label phase II Remodel WM3 trial

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Withou

The aim of this study is to evaluate if standard chemoimmunotherapy (FCR, BR) in frontline treatment of physically fit CLL patients without del17p or TP 53 mutation can be replaced by comb...

A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities

This multicenter, single arm, non-interventional, observational study will evaluate the efficacy and safety of obinutuzumab in daily clinical practice in participants with chronic lymphocy...

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

This study is a multicentric, single arm phase II trial to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by Cisplatinum-Cytarabine-Dexamethasone (D...

A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients.

Follicular lymphoma (FL) is an indolent yet incurable lymphoma characterized by initial responses to standard therapies, invariably followed by shorter disease free intervals. Obinutuzumab...

A Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation

This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).

Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL)

The goal of this clinical research study is to learn if atezolizumab and obinutuzumab (either with or without ibrutinib) can help control CLL. The safety of this drug combination will also...

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Quick Search
Advertisement
 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

review and buy Obinutuzumab market research data and corporate reports here

Channels Quicklinks